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Abstract 
The growth hormone secretagogue receptor type 1a (GHSR1a) has the highest 
constitutive activity of any G protein coupled receptor (GPCR). GHSR1a mediates the 
action of the hormone ghrelin and, its activation increases transcriptional and electrical 
activity in hypothalamic neurons. It is known that GHSR1a is present at some specific 
GABAergic presynaptic terminals; however, its impact on neurotransmitter release remains 
elusive. The voltage gated calcium channels, CaV2.1 and CaV2.2, control neurotransmitter 
release at presynaptic terminals and their activities are modulated by many GPCRs. Here 
we show that constitutive as well as agonist-dependent GHSR1a activation trigger a strong 
impairment of both CaV2.1 and CaV2.2 currents in rat and mouse neurons and in a 
heterologous expression system. Constitutive GHSR1a activity reduces CaV2 currents by a 
Gi/o-dependent mechanism that involves persistent reduction in channel density at plasma 
membrane, whereas, ghrelin-dependent GHSR1a inhibition is reversible and involves 
altered CaV2 current gating via a Gq-dependent pathway. Thus, we show that GHSR1a 
differentially inhibits CaV2 channels by Gi/o- or Gq-protein pathways depending on its 
activation mode. Moreover, we present evidence suggesting that GHSR1a-mediated 
inhibition of CaV2 impairs GABA release in hypothalamic neurons, a mechanism that could 
contribute to neuronal activation by the disinhibition of postsynaptic neurons.  
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Introduction 
GHSR1a is a G-protein coupled receptor (GPCR) highly expressed in the 
hypothalamus (Zigman et al., 2006). Ghrelin, the natural GHSR1a agonist, is a potent 
growth hormone secretagogue and it is the only known orexigenic peptide hormone 
(Nakazato et al., 2001). Ghrelin-induced GHSR1a activation in soma and dendrites 
regulates gene transcription and increases electrical activity in neurons (Nakazato et al., 
2001; Cowley et al., 2003; Diano et al., 2006; Andrews et al., 2008; Shi et al., 2013; 
Ribeiro et al., 2014). In addition, GHSR1a activation modulates neurotransmitter release at 
presynaptic terminals (Cowley et al., 2003; Cui et al., 2011; Yang et al., 2011). Otherwise, 
the modulation of presynaptic voltage gated calcium channels (CaV2.1 and CaV2.2) is a 
well-established mechanism by which GPCRs regulate neurotransmitter release at central 
synapses (Catterall and Few, 2008; Zamponi and Currie, 2013). However, the potential 
role of GHSR1a regulating CaV2 channels has not been tested.  
GHSR1a displays two uncommon features: a high constitutive activity and multiple 
signaling cascades that greatly increase the complexity of this receptor’s function. 
Constitutive GHSR1a activity is about 50% of the maximum activity triggered by saturating 
concentrations of ghrelin (Holst et al., 2003), and it is proposed to contribute to the 
physiological roles of the ghrelin/GHSR1a system (Petersen et al., 2009). However, the 
mechanisms by which constitutive GHSR1a activity regulates neuronal activity in 
hypothalamic neurons remain poorly understood. On the other hand, it is well known that 
GHSR1a activates Gq proteins (Howard et al., 1996; Holst et al., 2003), recent reports 
indicate that other G proteins, such as Gi/o and G12/13, and also G protein independent 
pathways, such as β-arrestin recruitment, can mediate GHSR1a actions (Bennett et al., 
2009; Evron et al., 2014). 
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Here, we used a combination of genetic and pharmacological manipulations of 
GHSR1a activity in order to get insights of the presynaptic role of the ghrelin/GHSR1a 
system. Overall, we show that both constitutive and ghrelin-dependent GHSR1a activities 
inhibit CaV2.1 and CaV2.2 and, as a consequence, GABA release in hypothalamic 
neurons. We also found fundamental differences in the mechanisms of CaV2 inhibition by 
constitutive and agonist dependent modes of GHSR1a activation; including the signaling 
cascades involved and the fact that  constitutive activity reduces membrane channel 
protein levels. Moreover, we propose that this GHSR1a-depedent regulation of presynaptic 
function may play a role under fasting, when GHSR1a expression in the hypothalamus is 
increased. 
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Materials and Methods 
Animals 
Sprague-Dawley rats and GHSR-eGFP reporter mice (STOCK Tg(Ghsr-
EGFP)KZ65Gsat/Mmucd, #030942-UCD, Mouse Mutant Regional Resource Center, 
University of California, United States) were bred at the animal facility of the IMBICE. We 
housed the animals in a 12 hour light/dark cycle in a climate controlled room (22 °C) with 
ad libitum access to water and food, except when indicated. We carried out this study in 
strict accordance with the recommendations of the Guide for the Care and Use of 
Laboratory Animals of the National Research Council, USA, and all efforts were made to 
minimize suffering. All experimentation received approval from the Institutional Animal 
Care and Use Committee of the IMBICE.  
 
Rat neuronal primary cultures 
Neuronal cultures were obtained from Sprague-Dawley rats at embryonic day 16-
17. The procedure protocol was similar to the one described in (Raingo et al., 2012). 
Briefly, we anesthetized pregnant rats with chloral hydrate (500 mg/kg) and removed the 
embryos. We exposed the embryo brains and placed them on the dorsal face to remove 
the hypothalamus with forceps. We placed the blocks of tissue in sterile Hank’s solution, 
and, after two washes, we dissociated the cells at 37 °C for 20 min with Hank´s solution 
containing trypsin 0.25 mg/ml (cat#L2700-100, Microvet, Buenos Aires, Argentina) and 
deoxyribonuclease I from bovine pancreas 0.28 mg/ml (cat#D5025, Sigma Aldrich, 
Missouri, United States), then we added 300 μl of Fetal Bovine Serum (FBS, cat#1650-01, 
Internegocios, Buenos Aires, Argentina) to stop the enzyme digestion. We mechanically 
dissociated the cells using several glass pipettes with consecutive smaller tips diameters. 
We plated 70,000 cells on 12 mm diameter glasses previously treated with poly-L-lysine 
(cat#P8920, Sigma Aldrich) and laid over 15 mm diameter wells. We incubated the cells at 
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37 °C in a 95% O2 and 5% CO2 atmosphere with Dulbecco Modified Eagle Medium 
(DMEM, cat# P3030, Microvet)/F12 1:1 medium supplemented with 10% FBS, 0.25% 
glucose, 2 mM glutamine (cat#21051-016, GIBCO, United States), 3.3 μg/ml insulin 
(Nordisk Pharm Ind, Inc, North Carolina, United States), 5 U/ml penicillin G sodium salt 
(Richet, Buenos Aires, Argentina), 5 μg/ml streptomycin (Richet), 40 μg/ml gentamicin 
sulfate salt (Richet) and 1 % vitamin solution (cat#L2112-100, Microvet). On the fourth day 
in culture, we replaced half of the incubation medium with fresh medium containing 
cytosine β-D-arabinofuranoside (AraC, cat# C1768, Sigma Aldrich) to reach a final 
concentration of 5 μM. 
 
Mouse neuronal primary cultures 
We used embryonic day 16-17 GHSR-eGFP reporter mice. The procedure protocol 
was similar to the one described above. The culture conditions were the same except for 
the addition of B27 supplement (1:50) (cat#17504-044, GIBCO) to the incubation medium.  
 
Rat neuron transfections 
At the 6th day in culture, we transfected rat neurons with GHSR1a-YFP, GHSR1a-
A204E-YFP or eGFP containing plasmids using calcium phosphate technique (Jiang and 
Chen, 2006). We performed patch clamp recordings on green fluorescent and non-green 
neurons after 48 h in culture. 
 
HEK 293T cells culture and transfection 
For patch clamp experiments, we co-transfected 80% confluent HEK 293T cells 
with GHSR1a or GHSR1a-A204E and CaV2.1 (#AY714490) or CaV2.2 (#AF055477) and 
the calcium channel auxiliary subunits CaVα2δ1 (#AF286488) and CaVβ3 (#M88751) or 
CaVβ2a (#M80545) in a 1:1:1:1 molar ratio using Lipofectamine 2000 (Invitrogen). Also, for 
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GHSR1a constitutive activity studies, we decreased the amount of GHSR1a cDNA 
transfected as indicated in the results section. For some experiments, we co-transfected 
empty pcDNA3.1+, the C-terminal G protein coupled receptor kinase 2 (MAS-GRK2-ct) 
(Kammermeier and Ikeda, 1999; Raingo et al., 2007) or a Gαq dominant negative mutant 
(Gαq-Q209L/D277N, cat#GNA0Q000C0, Missouri S&T cDNA Resource Center, Missouri, 
United States). For imaging experiments, we replaced CaV2.1 and CaV2.2 by these 
proteins tagged with GFP. GHSR1a and GHSR1a-A204E clones were provided by Dr. 
Jacky Marie (Universités Montpellier I & II, France), CaV clones used for this study were a 
gift from Dr. Diane Lipscombe (Brown University, United States) except CaV2.1-GFP and 
CaV2.2-GFP that were provided by Erika S. Piedras-Renteria (Loyola University Chicago, 
United States) and Ricardo Felix (Centro de Investigación y de Estudios Avanzados del 
Instituto Politécnico Nacional, Mexico). 
 
F-ghrelin binding  
We transfected HEK 293T cells with 0.15 or 0.6 μg of GHSR1a or 0.6 μg of empty 
pcDNA3.1+ plasmid as a control. We incubated the cells with 0.4 mM fluorescein-ghrelin 
(F-ghrelin (McGirr et al., 2011)) in binding buffer (50 mM HEPES, pH 7.4, 5 mM MgCl2, 1 
mM CaCl2, 0.2% BSA, passed through a 0.45 μm filter). After 30 min, we washed the cells 
with PBS, we fixed them with formaldehyde 4%, and covered them with mounting media. 
We observed the cells with an Eclipse 50i Nikon microscope filtering with a 500 nm filter. 
We took photomicrographs with a DS-Ri1 Nikon camera and analyzed the 
photomicrographs with the ImageJ 1.48v software.  
 
Electrophysiology 
We recorded ionic currents with an Axopatch 200 amplifier (Molecular Devices, 
California, United States). We sampled data at 20 kHz and filtered at 10 kHz (-3 dB) using 
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pClamp8.2 software. We used recording electrodes with resistances between 2-4 MΩ 
when filled with internal solution. We admitted series resistances less than 6 MΩ and 
compensated 80% with a 10 s lag time. We subtracted currents leak on-line using a P/-4 
protocol (except for the measure of evoked and miniature postsynaptic currents). We 
performed all recordings at room temperature. 
i- Sodium and barium currents of primary neuronal cultures. We patch-clamped 7-
10 day in vitro rat and mouse neurons in voltage-clamp whole-cell mode. Internal pipette 
solution contained (in mM): 134 CsCl, 10 EGTA, 1 EDTA, 10 HEPES, 4 MgATP (pH 7.2 
with CsOH). We measured sodium currents with high sodium external solution containing 
(in mM): 135 NaCl, 4.7 KCl, 1.2 MgCl2, 2.5 CaCl2, 10 HEPES, 10 glucose (pH 7.4 with 
NaOH). To measure CaV currents, we replaced the external solution by a high barium 
solution with the neurons clamped at negative potentials. High barium solution contained 
(in mM): 10 BaCl2, 110 choline chloride, 20 tetraethyl-ammonium chloride, 1 MgCl2, 10 
HEPES, 10 glucose and 0.001 tetrodotoxin (TTX, cat# T8024, Sigma Aldrich) (pH 7.4 with 
CsOH). We held neurons at -80 mV and applied test pulses to 0 mV for 20 ms every 10 s. 
Current-voltage relationship (IV) protocol: we applied increasing square test pulses of 20 
ms of duration ranging from -60 to +50 mV every 5 s (Raingo et al., 2007). 
ii- Postsynaptic currents of primary neuronal cultures: We patch-clamped 10-17 day 
in vitro mouse neurons. Internal pipette solution contained (in mM): 115 Cs-
methanesulfonate, 10 CsCl, 5 NaCl, 10 HEPES, 20 tetraethylammonium chloride, 4 Mg-
ATP, 0.3 NaGTP, 0.6 EGTA and 10 lidocaine N-ethyl bromide (pH 7.2 with CsOH). The 
external solution used was the high sodium solution described above, containing 10 μM 6-
cyano-7-nitroquinoxaline-2,3-dione (Alomone Labs, Jerusalem, Israel) in order to isolate 
inhibitory postsynaptic currents (IPSCs). To elicit evoked responses, we delivered 
electrical stimulation through parallel platinum electrodes (duration, 1 ms; amplitude, 20 
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mA) while neurons were held at -80 mV. We added 1 μM TTX in order to record miniature 
IPSCs (mIPSCs). 
iii- Calcium currents of transiently transfected HEK 293T cells. We performed 
whole-cell patch clamp recordings on transfected HEK 293T cells. The internal solution 
was the same described for sodium and barium currents. External solution contained (in 
mM): 2 CaCl2, 140 choline chloride, 1 MgCl2, 10 HEPES (pH 7.4 with CsOH). Test pulses 
protocol: we applied square pulses from -100 mV to 10 mV for 15 ms every 10 s. Pre-
pulse protocol: we applied a pre-pulse of 15 ms at +80 mV 12.5 ms before the test pulse to 
remove effectively all voltage-dependent inhibition of CaV (Raingo et al., 2007; Lopez Soto 
and Raingo, 2012). This protocol has no effect on both CaV2.1 and CaV2.2 control current 
densities (CaV2.1 currents without pre-pulse = -54.60 ± 16.97 pA/pF vs. with pre-pulse = -
54.27 ± 16.92 pA/pF, n=13, p>0.05; and CaV2.2 currents without pre-pulse = -46.28 ± 
14.53 pA/pF vs. with pre-pulse = -45.38 ± 14.23 pA/pF, n=8, p>0.05, Paired t-tests). 
Current-voltage relationship (IV) protocol: we applied increasing square test pulses of 20 
ms of duration ranging from -60 to +50 mV every 5 s (Raingo et al., 2007). 
Imaging  
We transfected HEK 293T cells with CaV2.1-GFP or CaV2.2-GFP, its auxiliary 
subunits (CaVα2δ1 and CaVβ3) and GHSR1a or GHSR1a-A204E as previously described. 
48 h after transfection, we replaced the culture medium by 1 ml of 1 μg/ml membrane 
marker solution (CellMaskTM Orange Plasma membrane Stain, cat# c10045, Molecular 
probes, California, United States) and kept the cells at 37ºC for 1 min. Then, we washed 
three times with PBS. Finally, we removed almost all the PBS volume and placed a clean 
coverslip over the cell layer. We obtained fluorescence photomicrographs with an Eclipse 
50i optical fluorescence microscope, equipped with B2A and G2A filters and with a Nikon 
DS-Ri1 camera. We performed the analysis on photomicrographs with FIJI free software, 
using the CellMask red signal to mark out the plasma membrane and quantify green 
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fluorescence intensity in both the internal area (excluding plasma membrane) and the total 
area of each cell as integrated density. We calculated the fluorescence intensity 
corresponding to the membrane as a % of the averaged intensity of the control condition 
(co-expressing GHSR1a-A204E). 
 
Western-blots 
We used Lipofectamine Plus reagent (Invitrogen) to transfect HEK 293T cells with 
CaV2.1 o CaV2.2, the CaV channel auxiliary CaVα2δ1 and CaVβ3 subunits, as well as the 
GHSR1a and the GHSR1a-A204E or the pCDNA3.1 empty vector. We extracted 
membrane protein using a membrane protein extraction kit (cat# K268-50, BioVision) as 
reported elsewhere (Gandini et al., 2014). For each condition, we used six 100 mm culture 
plates of HEK 293T cells expressing CaV channels. We determined cytosolic and plasma 
membrane protein concentration using the bicinchoninic acid assay. Briefly, 40/50 μg of 
protein samples were boiled for 5 min in protein-loading buffer (1.7% SDS, 0.1 M 2-
mercaptoethanol, 5% glycerol, 58 mM Tris–Cl, and 0.002% bromophenol blue; pH 6.8), 
resolved in 7% SDS-polyacrylamide gels and transferred to nitrocellulose membranes 
(Immobilon, Millipore). After blocking with 5% nonfat dry milk in Tris-buffered saline Tween 
20 (TBST; 100 mM Tris–Cl, 0.9% (w/v) NaCl, and 0.2% Tween 20; pH 7.5), we incubated 
membranes overnight with primary antibodies: anti-CaV2.1 (1: 300 in TBST 2.5% milk, 
Alomone Laboratories cat# ACC-001), anti-CaV2.2 (1:200 in TBST, Calbiochem cat# 
681505), anti-Cadherin (1:200 in TBST, Zymed cat# 71-7100), anti-AKT (1:15000 in TBST, 
Santa Cruz Biotechnology, Texas, United States, cat# sc-81434) and anti-Hsp90 (1:2000 
in TBST, Cell Signaling cat# 4875). Then, we washed membranes and incubated them 
with horseradish peroxidase (HRP)- conjugated secondary antibodies (Anti-rabbit HRP, 
1:5000 in TBST Jackson Inmunolabs cat# 111-035-003; Anti-mouse HRP; 1:5000 in TBST 
Jackson Inmunolabs cat# 115-035-033) diluted in TBST-5% nonfat dry milk. For semi-
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quantitative analysis, we normalized CaV channels signal to the Cadherin signal. We used 
the MacBiophotonics ImageJ program (National Institutes of Health) for densitometry 
analysis. 
 
Ex-vivo determination of [3H]-GABA release in Arcuate nucleus (ARC) 
We euthanized ad-libitum fed and 48 h fasted mice by live decapitation. We 
extracted brains, placed them briefly in cold PBS, and sectioned them into 1-mm coronal 
slices by using a stainless steel mouse brain matrix. We excised small punches of tissue 
corresponding to the known location of the ARC, as compared to the mouse brain atlas 
{Paxinos, 2001 #68}, using a 15-g needle. We incubated the ARC micro-dissections on 
Krebs-Ringer Bicarbonate Buffer (KRBB) saturated with 95% O2 and 5% CO2 for 10 min at 
37 °C. Then, we incubated with [3H]-GABA (367cpm/ml, with a specific activity of 92.1 
Ci/mmol) (Perkin Elmer) in KRBB for 20 min to fill synaptic vesicles with the tracer and we 
performed two washes with KRBB. After that, we incubated ARC micro-dissections for 10 
min with fresh KRBB containing 56 mM KCl. Finally, we collected the medium, mixed it 
with 150 μl of scintillator (Ecolite) and measured the radioactivity in a β-counter (Tracor 
Analytic). 
 
qRT-PCR analysis  
We euthanized ad-libitum fed and 48 h fasted mice by live decapitation. We 
extracted brains, placed them briefly in cold diethylpyrocarbonate-PBS, and excised small 
punches of tissue corresponding to the ARC, as explained above. We then performed 
qRT-PCR analysis as described in (Chuang et al., 2011a). Briefly, we isolated total RNA 
from these punches using RNA STAT-60 (Tel-Test Inc.). We treated the RNA with RNase-
free DNase (Roche) and reverse-transcribed into cDNA with SuperScript II reagents 
(Invitrogen). We performed a quantitative PCR using an Applied Biosystems 7900HT 
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Sequence Detection System and SYBR Green chemistry (Applied Biosystems). Primers 
were mGHSR-QF1, 5’-ACCGTGATGGTATGGGTGTCG-3’, and mGHSR-QR1, 5’-
CACAGTGAGGCAGAAGACCG-3`, they amplified a product within exon 2 of the ghsr 
gene. We confirmed these results  by a second set of specific primers, one of which is 
located in exon 1 of the ghsr gene (mGHSR-QF3 [5’-ATCTCCAGTGCCAGGCACTGCT-
3’]) and the other of which is located in exon 2 (mGHSR-GR3 [5’- 
AATGGGCGCGAGCAGCAGGAA-3’]) of the ghsr gene. The mRNA relative levels were 
expressed relative to the housekeeping gene 36B4 and calculated by the comparative 
threshold cycle (ΔCt) method (Kurrasch et al., 2004). The data are presented as a 
percentage of levels observed in wild-type ARC punches. 
 
Drugs 
We used ghrelin esterified with n-octanoic acid (cat# PI-G-03, Global Peptide, 
Colorado, United States); a GHSR1a inverse agonist, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-
Substance P (SPA, cat# sc-361166, Santa Cruz Biotechnology); the inhibitor of Gs protein, 
cholera toxin (ChTx, cat# C8052, Sigma Aldrich); a specific inhibitor of Gi/o protein, 
pertussis toxin (PTx, cat# P7208, Sigma Aldrich); the CaV2.1 blocker, ω-agatoxin-IVA (cat# 
4256-s, Peptides International, Kentucky, United states); the CaV2.2 blocker, ω-conotoxin-
GVIA (cat# C-300, Alomone lab, Israel). 
 
Statistics  
We analyzed and plotted the data using the OriginPro 8 (OriginLab Corp., 
Massachusetts, United States) and GraphPad Prism 5 (GraphPad Software Inc., 
California, United States). We examined the normal distribution of data by Kolmogorov-
Smirnov test. The statistical significance (p < 0.05) was determined by one-sample, paired-
sample, two-sample t-test, Mann-Whitney test, ANOVA with Dunnett’s or Tukey’s post-test 
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or, non-parametric Kruskal-Wallis test with Dunns post-test according to the normality 
results and the experiments. We expressed data as mean ± standard error with the 
number of observations in brackets.  
 
Results 
 
Constitutive and ghrelin-dependent GHSR1a activities differentially inhibit CaV2 
currents in a heterologous expression system 
 
We first examined the effect of GHSR1a and GHSR1a-A204E, a mutant lacking 
constitutive activity (Pantel et al., 2006), on cloned CaV2.1 and CaV2.2 channels. We co-
expressed GHSR1a and CaV2 in a 1:1 molar ratio (0.6 µg of receptor cDNA per 
transfection) and measured calcium currents in HEK 293T cells. Calcium currents were 
significantly smaller in cells co-expressing GHSR1a and CaV2, as compared to those 
expressing CaV2 alone. By contrast, CaV2 currents in cells expressing GHSR1a-A204E 
were not different from control recordings. We next tested if agonist-independent 
GHSR1a-induced inhibition of CaV2 varies with GHSR1a expression levels. Thus, we 
measured CaV2 currents in cells transfected with CaV2.1 or CaV2.2 channels and different 
amounts of GHSR1a plasmid and found that CaV2 current amplitudes were inversely 
proportional to GHSR1a cDNA amount per transfection (Figure 1A). Moreover, we found 
that F-ghrelin binding positively correlated with the level of GHSR1a cDNA used in the 
transfection (Figure 1B). Then we measured basal CaV2 currents in cells expressing 
GHSR1a  with or without the pre-incubation with the GHSR1a inverse agonist substance P 
analog (SPA, 1 µM) for 16 h and we found no significant difference with the currents  from 
cells co-expressing GHSR1a-A204E (Figure 1C). To assess ghrelin-dependent GHSR1a 
action on CaV2 currents, we used GHSR1a-A204E, which lacks constitutive activity but 
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exhibits activation by agonist binding. Application of a saturating dose of ghrelin (0.5 µM, 
(Pantel et al., 2006)) inhibited both CaV2 subtypes, but it was more effective on CaV2.2 as 
compared to CaV2.1 currents (44.5 ± 6.9 % n = 8 vs. 15.4 ± 3.9 %, n = 5, respectively at 
0.6 µg of receptor cDNA; t-test, p = 0.01). Moreover, ghrelin application inhibited in the 
same magnitude the CaV2.1 and CaV2.2 currents in cells expressing either GHSR1a or 
GHSR1a-A204E, and this inhibition was independent of GHSR1a expression levels, being 
saturated at very low amounts of cDNA (Figure 1D). 
We obtained two more sets of evidence toward two differential inhibitory 
mechanisms of constitutive and ghrelin-evoked GHSR1a’s effects on CaV2 currents: 
ghrelin application inhibits calcium currents in HEK 293T cells expressing CaV2.1 or 
CaV2.2 and GHSR1a in a 1:1 molar ratio pre-incubated with SPA, despite the fact that 
constitutive GHSR1a activity is blocked (Figure 2A). In addition, we found that acute 
application of SPA was unable to remove CaV2 inhibition by constitutive GHSR1a activity 
(Figure 2B).  
Thus, our data shows that constitutive GHSR1a activity inhibits CaV2.1 and CaV2.2 
channels by a long term mechanism that depends on GHSR1a expression levels. By 
contrast, ghrelin-dependent GHSR1a activity is more effective to inhibit CaV2.2 as 
compared to CaV2.1 currents and this inhibition is fast and independent of GHSR1a 
expression levels. 
 
Two different signaling cascades are involved in CaV2 inhibition by constitutive and 
ghrelin-dependent GHSR1a activity  
 
Next, we tested the hypothesis that differential mechanisms mediate the inhibition 
of CaV2 channels by constitutive and ghrelin-dependent GHSR1a activities. We examined 
the signaling pathways engaged by GHSR1a that result in CaV2 inhibition. We assessed 
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the effectiveness of ghrelin-induced activation of GHSR1a-A204E on CaV2.2 channels 
expressed in HEK 293T cells. Neither the Gs protein inhibitor Cholera toxin (ChTx, 500 
ng/ml) nor the Gi/o protein inhibitor Pertussis toxin (PTx, 500 ng/ml) affected ghrelin-
mediated inhibition of CaV2.2 currents (Figure 3A). We therefore used a mutant form of 
Gαq (GqDN) that acts as a dominant negative interfering with Gq-dependent signaling (Yu 
and Simon, 1998; Lauckner et al., 2005) and we found that GqDN occluded the inhibitory 
actions of ghrelin on CaV2.2 (Figure 3A).  
Then, we tested if the same G protein signaling pathway also mediates the 
inhibitory actions of constitutive GHSR1a activity on CaV2.2 currents independently of 
ghrelin. We found that neither GqDN nor pre-treatment with ChTx affect CaV2.2 current 
amplitude in cells expressing GHSR1a. By contrast, CaV2.2 currents in cells expressing 
GHSR1a pre-treated with PTx were not different from the currents recorded in cells 
expressing GHSR1a-A204E (Figure 3B). This result suggests that GHSR1a inhibits CaV2.2 
channels through Gi/o protein activation by an agonist-independent mechanism. 
GPCR-mediated inhibition of CaV2.2 is mediated for at least 3 different G proteins 
and the downstream mechanisms can be voltage-sensitive or voltage-insensitive (Zamponi 
and Currie, 2013). The most common form of Gi/o-dependent inhibition of CaV2.2 channels 
involves direct binding of Gβɣ to the channel, and it is relieved by strong depolarizing pre-
pulses (voltage-sensitive) (Ikeda, 1996; Raingo et al., 2007; Lipscombe et al., 2013). On 
the other hand, several Gα protein subtypes (Gq, Gi/o and Gs) activate voltage-insensitive 
forms of CaV2 inhibition (Kammermeier and Ikeda, 1999; Kammermeier et al., 2000; 
Zamponi and Currie, 2013; Agosti et al., 2014). We found that inhibition of CaV2.2 
channels by ghrelin-induced activation of GHSR1a-A204E is not relieved by +80 mV pre-
pulses, consistent with a purely voltage-independent mechanism and a Gq-mediated 
pathway (Figure 3C). However, it is known that Gq-mediated inhibition of CaV2.2 channels 
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turns into a voltage sensitive inhibition by substituting the CaVβ3 for a membrane bound 
form, CaVβ2a (Keum et al., 2014). Thus, we assayed ghrelin-mediated inhibition of CaV2.2 
with CaVβ2a as auxiliary subunit. We found that ghrelin-mediated inhibition of CaV2.2 was 
not only reduced, as compared to the inhibition of CaV2.2 channels formed by CaVβ3, but 
also completely reversed by +80 mV pre-pulses (Figure 3C). Moreover, we co-expressed 
the MAS-GRK2-ct peptide to sequester Gβɣ (Kammermeier and Ikeda, 1999; Raingo et al., 
2007) and found that this maneuver fully occluded the inhibitory actions of ghrelin-
GHSR1a-A204E on CaV2.2 channels co-expressed with either CaVβ2a or CaVβ3. Taken 
together, our results demonstrate that ghrelin-mediated GHSR1a activation inhibits CaV2.2 
currents by a mechanism that involves Gq, Gβɣ subunits of G proteins and whose voltage 
dependency relies onthe CaVβ subtype. On the other hand, we found that inhibition of 
CaV2.2 by constitutive GHSR1a activity is unaltered by strong pre-pulses to +80 mV, CaVβ 
subtype or Gβɣ sequestration (Figure 3D). Thus, our results suggest that agonist-
dependent and agonist-independent forms of CaV2.2 inhibition by GHSR1a signal through 
different pathways. 
 
CaV2 inhibition by constitutive GHSR1a activity is associated with a reduced 
channel density at the plasma membrane 
 
Based in our results showing that the GHSR1a inverse agonist, SPA, requires long 
pre-incubation periods in order to occlude constitutive inhibition of CaV2 by GHSR1a, we 
decided to test if surface CaV2 density was affected by constitutive GHSR1a activity. First, 
we monitored the presence of CaV2 channels in the plasma membrane, using CaV2.1 and 
CaV2.2 channels tagged with GFP (CaV2.1-GFP and CaV2.2-GFP) that we have confirmed 
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are functional in our experimental conditions (CaV2.1-GFP current -47.0 ± 14.5 pA/pF, n = 
9; CaV2.2-GFP current = -51.8 ± 12.3 pA/pF, n = 5). Then, in order to identify the surface 
location of the GFP fluorescence signal, we used the red fluorescent membrane marker 
CellMaskTM (Cogger et al., 2010). We found that CaV2.1-GFP and CaV2.2-GFP -
associated fluorescence signal was significantly lower in cells co-expressing GHSR1a, as 
compared to those co-expressing GHSR1a-A204E or those expressing GHSR1a and pre-
incubated with SPA or PTx (Figure 4A). Next, we used western blots in order to confirm 
that the CaV2.1 and CaV2.2 membrane protein level is decreased when cells co-express 
GHSR1a. We used HEK 293T cells transfected with CaV2.1-GFP or CaV2.2-GFP, as well 
as GHSR1a, GHSR1a-A204E or the pCDNA3.1 empty vector. By using cadherin as a 
plasma membrane marker, and AKT and Hsp90 as cytoplasmic protein markers, we found 
that CaV2.1 and CaV2.2 protein quantity decreased in the plasma membrane protein 
fraction when cells co-express GHSR1a, while GHSR1a-A204E co-expression failed to 
affect the amount of CaV2.1 and CaV2.2 plasma membrane protein (Figure 4B). In 
summary, our data suggest that constitutive GHSR1a activity reduces surface expression 
of CaV2.1 and CaV2.2 channels by a Gi/o-dependent mechanism. 
 
Constitutive and ghrelin-dependent GHSR1a activities inhibit native N- and P/Q-type 
currents 
 
In order to test the effect of GHSR1a activities on calcium channels in native 
conditions, we used hypothalamic primary neuronal cultures of GHSR-eGFP reporter mice 
in which GHSR1a expressing neurons are identifiable by green fluorescent signal (Mani et 
al., 2014). We first compared CaV currents recorded in GHSR1a-positive (GHSR1a+) and 
GHSR1a-negative (GHSR1a-) neurons. CaV currents were inhibited by 100 µM CdCl2 (% 
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of inhibition: GHSR1a+=99.91±2.51 %, n=5; GHSR1a-=99.28±0.98 %, n=5, both n.s. vs. 
100%, t-test, p>0.05). CaV currents recorded in GHSR1a+ neurons displayed the same 
voltage-dependency than those recorded in GHSR1a- neurons but they were significantly 
smaller (Figure 5A and B). Importantly, ghrelin application inhibited CaV currents in 
GHSR1a+ but not in GHSR1a- neurons (Figure 5A). We used ω-conotoxin-GVIA and ω-
agatoxin-IVA to quantify the contribution of N- (CaV2.2) and P/Q-type (CaV2.1) channels, 
respectively, in this experimental system. We found that both types of current were 
significantly smaller in GHSR1a+ compared to GHSR1a- neurons in the presence or 
absence of ghrelin (Figure 5C). However, TTX-sensitive NaV currents in GHSR1a+ and 
GHSR1a- neurons were not different (p>0.05, t-test; Figure 5D). Thus, GHSR1a+ neurons 
have reduced N- and P/Q-type currents as compared to GHSR1a- neurons, and ghrelin 
inhibits those currents only in GHSR1a+ neurons. 
In order to dissociate the effect of constitutive and ghrelin-dependent GHSR1a 
activities on native calcium channels, we transfected either GHSR1a-YFP or GHSR1a-
A204E-YFP in hypothalamic rat cultured neurons, which express minimal levels of 
endogenous GHSR1a under our experimental conditions (6±2 % of neurons bind F-
ghrelin, n=3, independent cultures). CaV currents recorded in neurons expressing 
GHSR1a-YFP were significantly smaller as compared to those recorded in either neurons 
expressing eGFP, GHSR1a-A204E-YFP or non-transfected neurons (Figure 6A). Ghrelin 
inhibited the same relative percentage of CaV currents in neurons expressing either 
GHSR1a-YFP or GHSR1a-A204E-YFP while it failed to affect CaV currents in neurons 
expressing eGFP or non-transfected neurons (Figure 6B, normalized current traces). We 
next used ω-conotoxin-GVIA and ω-agatoxin-IVA to test CaV2 subtypes contribution to the 
total CaV current in our experimental conditions. We found a smaller contribution of CaV2.1 
and CaV2.2 in GHSR1a-YFP expressing neurons as compared to the contribution found in 
GHSR1a-A204E-YFP expressing neurons. Additionally, calcium currents in presence of 
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ghrelin showed a reduced contribution of CaV2 in both GHSR1a-YFP and GHSR1a-
A204E-YFP expressing neurons (Figure 6C). Importantly, TTX-sensitive NaV currents were 
not affected among the different experimental conditions (Figure 6D). Thus, constitutive 
and ghrelin-dependent GHSR1a activities inhibit native N- and P/Q-type calcium currents 
in hypothalamic neurons. 
 
Constitutive and ghrelin-dependent GHSR1a activities reduce GABA release from 
hypothalamic explants 
 
In previous studies we have suggested that GHSR1a activity decreases inhibitory 
tone on hypothalamic neurons (Cabral et al., 2012). Thus, we next evaluated if GHSR1a 
activity affects GABA release from explants of the arcuate nucleus (ARC), an 
hypothalamic nucleus where GHSR1a is highly expressed (Zigman et al., 2006) and 
GABA release is essential for food intake regulation (Wu et al., 2009). In order to explore 
the role of constitutive GHSR1a activity, we used 48 h fasted mice, in which hypothalamic 
GHSR1a mRNA levels were 1.5-fold higher in comparison to levels found in ad libitum fed 
mice (Figure 7A, right). We studied the [3H]-GABA release from explants of ARC and we 
found a significant reduction of [3H]-GABA release stimulated by high K+ in explants from 
fasted mice as compared to release detected in explants from ad libitum fed mice (Figure 
7A, left). Thus, our data show that fasting-induced increase of GHSR1a expression levels 
correlates with an inhibition of GABA release from ARC neurons. 
In order to test if constitutive GHSR1a activity-displayed inhibition of N- and P/Q-
type currents impacts on GABA release, we recorded IPSCs in hypothalamic neuronal 
cultures from GHSR null mice transduced with either GHSR1a-YFP or GHSR1a-A204E-
YFP lentiviral vectors, which allow a high percentage of GHSR1a expressing neurons. In 
these experimental conditions, we found a reduced IPSC size triggered by electrical 
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stimulation in GHSR1a-YFP expressing cultures in comparison with both GHSR1a-A204E-
YFP expressing cultures and non-transduced cultures (Figure 7B). Moreover, we found 
that acute ghrelin application reduced ~ 20 % the IPSC peak in cultures expressing either 
GHSR1a-YFP or GHSR1a-A204E-YFP (Figure 7C, normalized IPSC recordings), 
indicating that both GHSR1a variants are functional and that ghrelin-dependent GHSR1a 
activation can further inhibit IPSCs. Finally, we recorded GABAergic postsynaptic 
responses stimulated by hyperosmotic solution in presence of TTX, a maneuver known to 
release neurotransmitter in a CaV-independent manner. We found no differences in these 
responses among non-transduced, GHSR1a-YFP transduced and GHSR1a-A204E-YFP 
transduced cultures suggesting that constitutive GHSR1a activity exclusively affects action 
potential dependent and CaV2-mediated GABAergic neurotransmission. Importantly, the 
size of spontaneous IPSCs was not different among conditions (Figure 7D) indicating the 
lack of a postsynaptic effects in the IPSC size reduction by GHSR1a activity. 
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Discussion 
We present evidence that GHSR1a, the GPCR with the highest constitutive activity, 
down-regulates CaV2.1 and CaV2.2 currents by a mechanism that is independent of its 
endogenous agonist, ghrelin, and involves Gi/o signaling and plasma membrane channel 
density reduction. We also show that ghrelin inhibits native and cloned CaV2.1 and CaV2.2 
currents via activation of GHSR1a by a different signaling cascade that involves Gq protein 
activation. These two fundamentally different mechanisms could differentially contribute to 
regulate presynaptic Ca2+ entry and transmitter release from hypothalamic neurons. 
 
Presynaptic CaV2 channels inhibition by GPCRs is an important mechanism 
mediating the effects of many transmitters and drugs that control neurotransmitter release 
(Catterall and Few, 2008). GHSR1a is expressed at axonal terminals and a presynaptic 
role for this receptor has been suggested (Cowley et al., 2003; Cui et al., 2011; Yang et 
al., 2011; Ribeiro et al., 2014). In general, ghrelin/GHSR1a system stimulates electrical 
and transcriptional activity in neurons (Cowley et al., 2003; Andrews et al., 2009; Shi et al., 
2013). Also, it has been shown that GHSR1a signaling augments cytosolic Ca2+ levels in 
hypothalamic neurons (Howard et al., 1996; Chuang et al., 2011b; Yang et al., 2011). 
Here, we propose a novel mechanism that could potentially contribute to neuronal 
activation of hypothalamic neurons by controlling CaV2 channels located at the presynaptic 
terminals of inhibitory input neurons. Moreover, in agreement with previous data showing 
that GHSR1a can couple to several different pathways, we demonstrate that two 
fundamentally different mechanisms govern ghrelin dependent and ghrelin independent 
presynaptic CaV2 inhibition by GHSR1a. 
We show evidence that constitutive GHSR1a activity down regulates CaV2 channel 
density by a Gi/o-dependent signaling pathway. GHSR1a is typically thought to involve Gq 
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protein activation (Holst et al., 2003) although Gi/o involvement is also well documented 
(Bennett et al., 2009). Other GPCRs, such as the nociceptin receptor (opioid receptor-like 
receptor, ORL1) and metabotropic glutamate receptor subtype 1 (mGluR1), have been 
shown to inhibit CaV2 by agonist binding independent mechanisms that require GPCR and 
channel protein direct interaction (Kitano et al., 2003; Beedle et al., 2004). ORL1 is a Gi/o 
coupled receptor that inhibits CaV2.2 channels in dorsal root ganglion neurons, and it has 
been shown that basal and nociceptin-mediated ORL1 inhibition of CaV2.2 shared a Gβγ-
mediated pathway since both are avoided by Gβγ sequestering or depolarizing pre-pulse 
voltage application (Beedle et al., 2004). In contrast, we show here that CaV2 current 
inhibition by constitutive GHSR1a activity differs from ghrelin-evoked effect as the former 
mode of inhibition is independent of Gβγ binding and involves cell surface channel density 
reduction.  
We found that ghrelin-dependent GHSR1a activity inhibits CaV2 channel by a rapid 
and reversible Gq-dependent signaling pathway. Gq activation generally inhibits CaV2 in a 
voltage independent manner. Several signaling pathways have been proposed to mediate 
calcium channel inhibition including PtdIns(4,5)P2 (PIP2) depletion from plasma 
membrane, increase of arachidonic acid production and protein kinases activation (Wu et 
al., 2002; Liu and Rittenhouse, 2003; Gamper et al., 2004; Suh et al., 2010). The CaV2 
inhibition induced by PIP2 depletion or arachidonic acid increment requires cytoplasmic 
subtypes of CaVβ (CaVβ3) and, as a consequence, both mechanisms fail to impair CaV2 
currents if channels contain the membrane anchored form of CaVβ, CaVβ2a (Heneghan et 
al., 2009; Suh et al., 2012). Accordingly, we found that the inhibition of CaV2.2 induced by 
ghrelin-evoked GHSR1a activation depends on the type of CaVβ subunit. In particular, the 
ghrelin-mediated CaV2.2 inhibition was significantly reduced and fully voltage-dependent 
when CaVβ2a was present while it was larger and voltage-independent in the presence of 
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CaVβ3. Additionally, we found that buffering Gβγ is enough to completely avoid the ghrelin-
mediated inhibition of CaV2.2 independently of the CaVβ subtype. Previous reports have 
shown the same dependency of Gβγ for other GqPCRs-mediated pathways (i.e. muscarinic 
type 1 and neurokinin type 1 receptors) (Kammermeier et al., 2000). Thus, our data 
support the notion that CaVβ2a in the channel complex switches the voltage dependency of 
CaV2 inhibition by occluding Gq subunit signaled effect and unmasks the inhibition by Gβγ 
direct binding as recently demonstrated by (Keum et al., 2014). 
Peripheral administration of ghrelin potently increases food intake (Nakazato et al., 
2001). Plasma ghrelin almost exclusively access the hypothalamic ARC, which expresses 
high levels of GHSR1a and is required for the orexigenic actions of peripheral ghrelin 
(Zigman et al., 2006; Schaeffer et al., 2013; Cabral et al., 2014). GABA release from ARC 
neurons is essential for food intake regulation (Wu et al., 2009) and GHSR1a is found at 
presynaptic terminals (Cowley et al., 2003; Yang et al., 2011). It has also been shown that 
GABA release by AgRP ARC neurons is required for ghrelin-induced food intake (Tong et 
al., 2008), and a ghrelin-induced reduction of GABA release has been proposed to 
mediate other hypothalamic actions of the hormone (Cabral et al., 2012). Thus, current 
results showing that ghrelin-induced GHSR1a activity inhibits native calcium channels, 
impairs CaV2 dependent GABA release from ARC explants and modify synaptic activity in 
hypothalamic neurons in culture offer a molecular mechanism that can mediate well 
established effects of ghrelin. In contrast, the physiological role of constitutive GHSR1a 
activity has been hard to highlight in in vivo settings. Here, we confirmed the fact that 
GHSR1a expression level is affected by the energy balance conditions, and that this 
change correlates with GABA release at the ARC level suggesting that GHSR1a 
constitutive activity may have functional implications (Holst et al., 2003; Kim et al., 2003; 
Pantel et al., 2006; Kineman and Luque, 2007; Liu et al., 2007). The facts that in vivo 
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administration of the GHSR1a inverse agonist SPA reduces food intake and body weight 
in rats (Petersen et al., 2009), and that mice lacking GHSR1a exhibit a more severe 
phenotype compared to ghrelin knockout mice have been also interpreted as indications of 
a physiological role of the constitutive GHSR1a activity (Uchida et al., 2013). Notably, the 
A204E mutation has been associated with short stature and dominant transmission in 
human beings (Pantel et al., 2006). However, further studies are required in order to 
explore the physiological implications of the GHSR1a-related molecular events that occur 
in a ghrelin-independent fashion.  
 
Current data open many intriguing questions including the physiological relevance 
of constitutive activity at synapses without ghrelin availability and mechanisms that 
regulate the agonist independent actions of GHSR1a. Interestingly, GHSR1a is also 
present in brain areas distant from circumventricular organs (Zigman et al., 2006) that are 
not accessed by plasma ghrelin (Cabral et al., 2013; Cabral et al., 2014). It has been 
proposed that GHSR1a located in obvious inaccessible areas to plasma ghrelin could be 
modulated by centrally-produced ghrelin (Cowley et al., 2003); however, more recent 
studies have clearly shown that ghrelin is not synthesized in the central nervous system 
(Sakata et al., 2009; Furness et al., 2011). Besides receptor expression levels, hetero-
dimerization of GHSR1a with other GPCRs could also serve as an alternative mechanism 
to modulate specific functions of this receptor, independently of ghrelin binding (Jiang et 
al., 2006; Rediger et al., 2011; Kern et al., 2012; Schellekens et al., 2013). Thus, more 
efforts will be required to get insight on the complexity of the GHSR1a/ghrelin actions in 
neurons. 
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FIGURE LEGENDS 
 
Figure 1. Constitutive and ghrelin-dependent GHSR1a activity inhibit CaV2 currents. A-
Representative ICa traces from HEK 293T cells transfected with CaV2.1 or CaV2.2, CaVα2δ1, 
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CaVβ3 and 0.6 μg of GHSR1a, GHSR1a-A204E or empty pcDNA3.1+ (control), and 
averaged ICa at different amounts of GHSR1a plasmid transfected. B- Representative 
microphotographies (left) and average fluorescent signal intensity (right) for the F-ghrelin 
binding in cells transfected with increasing amounts of GHSR1a plasmid. C- 
Representative ICa traces from cells co-transfected with CaV2.1 and CaV2.2, CaVα2δ1, 
CaVβ3 and 0.6 μg of GHSR1a or GHSR1a-A204E with or without 1 μM SPA pre-incubation 
(left), and the averaged ICa for each condition (right). D- Time courses and representative 
traces of ghrelin effect on ICa from cells expressing CaV2.1 or CaV2.2, CaVα2δ1, CaVβ3 and 
GHSR1a-A204E (left), and the averaged % CaV2.1 and CaV2.2 current inhibition at 
different amounts of GHSR1a plasmid transfected. ANOVA with Dunnett’s and Tukey’s 
post-test. * p < 0.05. 
 
Figure 2. Constitutive GHSR1a activity inhibits by a long term mechanism the CaV2 
currents preserving CaV2 current inhibition by ghrelin-dependent GHSR1a activity. A- 
Representative ICa traces (left) from HEK 293T cells expressing CaV2.1 (above) or CaV2.2 
(below), CaVα2δ1, CaVβ3 and GHSR1a pre-incubated with 1 μM SPA, before (control) and 
after (+ghrelin) 500 nM ghrelin application; and averaged % of ICa inhibition by 500 nM 
ghrelin (right) from HEK 293T cells expressing CaV2.1 or CaV2.2, CaVα2δ1, CaVβ3 and 
GHSR1a pre-incubated with 1 μM SPA or GHSR1a-A204E as control condition. B- Time 
courses of peak CaV2 currents (left) with the acute application of 1 µM SPA (gray bars) 
from HEK 293T cells expressing CaV2.1 (above) or CaV2.2 (below), CaVα2δ1, CaVβ3 and 
GHSR1a, and the averaged CaV2.1 or CaV2.2 currents before (control) and after (+SPA) 
acute application of 1 µM SPA.  
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Figure 3. CaV2.2 inhibition by constitutive and ghrelin-dependent GHSR1a activity are 
signaled by Gi/o and Gq proteins, respectively. A- Time course, representative traces and 
averaged ICa inhibition by 500 nM ghrelin in HEK 293T cells transfected with CaV2.2, 
CaVα2δ1, CaVβ3 and GHSR1a-A204E in control conditions or pre-incubated with 500 ng/ml 
of Cholera toxin (ChTx) or 500 ng/ml of Pertussis toxin (PTx), or co-transfected with a Gq 
dominant negative mutant (GqDN). B- Representative traces and averaged ICa in HEK 
293T cells expressing CaV2.2, CaVα2δ1, CaVβ3 and GHSR1a or GHSR1a-A204E, in control 
or pre-incubated with 500 ng/ml of ChTx or 500 ng/ml of PTx, or co-transfected with GqDN. 
C- Representative ICa in HEK 293T cells co-transfected with CaV2.2, CaVα2δ1, GHSR1a-
A204E and CaVβ3 or CaVβ2a without (control) or with (+ghrelin) 500 nM ghrelin without or 
with (+pp) a +80 mV pre-pulse application (left) and; averaged % of ICa inhibition by 500 
nM ghrelin in cells expressing CaV2.2, CaVα2δ1 and GHSR1a-A204E with the co-
expression of CaVβ3 or CaVβ2a and MAS-GRK2-ct and pre-pulse application (+pp) (right). 
D- Representative ICa traces from cells co-transfected with CaV2.2, CaVα2δ1, CaVβ3 and 
GHSR1a or GHSR1a-A204E with (+pp) or without (Control) the application of +80 mV pre-
pulse (left) and averaged ICa from HEK 293T cells expressing CaV2.2, CaVα2δ1, GHSR1a 
or GHSR1a-A204E, with the co-expression of CaVβ3 or CaVβ2a and MAS-GRK2ct and +80 
mV pre-pulse application (+pp) (right). ANOVA with Dunnett’s or Tukey’s post-test. * p < 
0.05. 
 
Figure 4- GHSR1a decreases surface CaV2.1 and CaV2.2 density. A- Photomicrographs 
and averaged percentages of green fluorescent plasma membrane signal of HEK 293T 
cells transfected with CaV2.1-GFP (left) and CaV2.2-GFP (right), its auxiliary subunits 
(Control) with GHSR1a or GHSR1a-A204E, pre-incubated or not with 1 µM SPA or 500 
ng/ml of PTx. Green and red signals correspond to the eGFP tag on CaV2 and the 
membrane marker CellMask™ respectively. Kruskal-Wallis with Dunns post-test * p < 
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0.01. B- Western blot analysis displaying the CaV2.1-GFP and CaV2.2-GFP protein level in 
the plasma membrane (PM) or the cytoplasmic (Cyt) fraction of HEK 293T cells 
transfected with CaV2.1-GFP or CaV2.2-GFP and its auxiliary subunits (Control) and co-
transfected with GHSR1a or GHSR1a-A204E(left) and averaged % of CaV2.1-GFP and 
CaV2.2-GFP PM protein level in each condition normalized against cadherin signal used as 
the plasma membrane loading control (right). Both AKT and Hsp90 as cytosolic markers.  
n = 2 and 3 for CaV2.1-GFP or CaV2.2-GFP, respectively. 
 
Figure 5- GHSR1a activity modulates native CaV2 currents in hypothalamic neurons from 
GHSR-eGFP reporter mice. A- Representative IBa traces and averaged IBa before (control) 
and after (+ghrelin) 500 nM ghrelin application in hypothalamic GHSR1a- and GHSR1a+ 
neurons. B- Averaged peak IBa -voltage (IV) relationships (evoked from a holding of -80 
mV), reversal (Vrev) and activation (V1/2) potentials midpoints (calculated by Boltzmann-
linear function) obtained from GHSR1a- and GHSR1a+ neurons. C- IBa time courses of 
application of 1 µM ω-conotoxin-GVIA (conoTx) and 0.2 µM ω-agatoxin-IVA (agaTx) with 
or without previous 500 nM ghrelin application from hypothalamic GHSR1a- (top) and 
GHSR1a+ neurons (center and bottom) (left). Averaged % of IBa sensitive to agaTx and 
conoTx from GHSR1a- and GHSR1a+ neurons, with (+ghrelin) or without 500 nM ghrelin 
application (right). D- Representative and averaged INa from GHSR1a- and GHSR1a+ 
neurons. Paired or two sample Student’s t-test and ANOVA with Dunnett’s post-test. * p < 
0.05. 
 
Figure 6- GHSR1a activity inhibits native CaV2 currents from rat hypothalamic neurons. A- 
Representative and averaged IBa from non-transfected (nt) and GFP, GHSR1a-YFP and 
GHSR1a-A204E-YFP transfected neurons. B- Normalized IBa traces before (control) and 
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after (+ghrelin) 500 nM ghrelin application and averaged % of IBa inhibition by ghrelin in 
each condition. C- IBa time courses of application of 1 µM ω-conotoxin-GVIA (conoTx) and 
0.2 µM ω-agatoxin-IVA (agaTx) with or without previous 500 nM ghrelin application from 
GFP, GHSR1a and GHSR1a-A204E transfected neurons (left). Averaged % of IBa 
sensitive to agaTx and conoTx from non-transfected (nt), GFP, GHSR1a and GHSR1a-
A204E transfected neurons, with (+ghrelin) or without 500 nM ghrelin application (right). D- 
Representative and averaged INa from non-transfected (nt) and GFP, GHSR1a and 
GHSR1a-A204E transfected neurons. ANOVA with Dunnett’s and Tukey’s post-test. * p < 
0.05. 
 
Figure 7- GHSR1a activity impacts on GABA release. A- [3H]-GABA release (left) and 
GHSR1a mRNA levels (right) from ARC-enriched explants from ad libitum fed or 48 h 
fasted mice. B- Representative traces and averaged IPSC size obtained from GHSR null 
primary cultured neurons transduced or not with GHSR1a-YFP and GHSR1a-A204E-YFP. 
C- Representative normalized traces and average values of IPSC with or without the 
application of 500 nM of ghrelin obtained from GHSR null primary cultured neurons 
transduced or not with GHSR1a-YFP and GHSR1a-A204E-YFP. D- Distribution of mIPSC 
size and averaged values for mIPSC frequencies and charge movement by 0.5 M sucrose 
solution application in GHSR null primary cultured neurons transduced or not with 
GHSR1a-YFP and GHSR1a-A204E-YFP. Student’s t-test (C) and ANOVA (A, B, D) with 
Dunnett’s post-test. * p < 0.05. 
 
